Weiping Zhou

2.3k total citations
33 papers, 1.4k citations indexed

About

Weiping Zhou is a scholar working on Epidemiology, Hepatology and Oncology. According to data from OpenAlex, Weiping Zhou has authored 33 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Epidemiology, 20 papers in Hepatology and 5 papers in Oncology. Recurrent topics in Weiping Zhou's work include Hepatitis B Virus Studies (18 papers), Hepatocellular Carcinoma Treatment and Prognosis (14 papers) and Liver Disease Diagnosis and Treatment (14 papers). Weiping Zhou is often cited by papers focused on Hepatitis B Virus Studies (18 papers), Hepatocellular Carcinoma Treatment and Prognosis (14 papers) and Liver Disease Diagnosis and Treatment (14 papers). Weiping Zhou collaborates with scholars based in China, Hong Kong and United States. Weiping Zhou's co-authors include Wan Yee Lau, Gang Huang, Jonathan Skinner, Ze‐Ya Pan, Nancy E. Morden, Ellen Meara, Zhenguang Wang, Wilson M. Powell, Lynn McClelland and A. James O’Malley and has published in prestigious journals such as New England Journal of Medicine, Journal of the American College of Cardiology and Hepatology.

In The Last Decade

Weiping Zhou

31 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Weiping Zhou China 18 706 583 281 200 189 33 1.4k
Wallis Marsh United States 21 659 0.9× 1.3k 2.3× 100 0.4× 1.3k 6.7× 64 0.3× 36 2.2k
Allison J. Kwong United States 19 1.0k 1.4× 1.4k 2.4× 233 0.8× 1.1k 5.4× 98 0.5× 88 2.1k
Hock Soo Ong Singapore 27 126 0.2× 241 0.4× 52 0.2× 1.0k 5.1× 337 1.8× 76 2.0k
Jennifer A. Flemming Canada 18 852 1.2× 991 1.7× 66 0.2× 427 2.1× 45 0.2× 94 1.5k
Chapy Venkatesan United States 16 1.1k 1.6× 807 1.4× 35 0.1× 287 1.4× 105 0.6× 24 1.4k
Kwok-Hung Lai Taiwan 14 652 0.9× 796 1.4× 22 0.1× 569 2.8× 51 0.3× 20 1.2k
James A. Knol United States 24 284 0.4× 521 0.9× 52 0.2× 986 4.9× 83 0.4× 76 1.8k
George Therapondos United States 32 1.8k 2.6× 2.1k 3.6× 278 1.0× 1.3k 6.6× 188 1.0× 90 2.9k
Diamantis I. Tsilimigras United States 15 146 0.2× 260 0.4× 96 0.3× 185 0.9× 149 0.8× 56 982
Cataldo Doria United States 23 262 0.4× 537 0.9× 223 0.8× 964 4.8× 82 0.4× 67 1.5k

Countries citing papers authored by Weiping Zhou

Since Specialization
Citations

This map shows the geographic impact of Weiping Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiping Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiping Zhou more than expected).

Fields of papers citing papers by Weiping Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weiping Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiping Zhou. The network helps show where Weiping Zhou may publish in the future.

Co-authorship network of co-authors of Weiping Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Weiping Zhou. A scholar is included among the top collaborators of Weiping Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weiping Zhou. Weiping Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Liu, Xiufeng, Yinying Lu, Weiping Zhou, et al.. (2024). Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition). Liver Cancer. 13(4). 355–375. 5 indexed citations
3.
Guo, Mengbiao, Linghao Zhao, Changchang Jia, et al.. (2023). Multiomics analyses reveal pathological mechanisms of HBV infection and integration in liver cancer. Journal of Medical Virology. 95(8). e28980–e28980. 4 indexed citations
4.
5.
Xu, Wenping, Jinpei Liu, Jifeng Feng, et al.. (2019). miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy. Gut. 69(7). 1309–1321. 88 indexed citations
6.
Tao, Qi-fei, Zhiheng Wang, Kongying Lin, et al.. (2019). Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3 cm – A retrospective cohort study. The American Journal of Surgery. 219(4). 717–725. 9 indexed citations
7.
Yang, Fan, Longteng Ma, Yuan Yang, et al.. (2019). Contribution of Hepatitis B Virus Infection to the Aggressiveness of Primary Liver Cancer: A Clinical Epidemiological Study in Eastern China. Frontiers in Oncology. 9. 370–370. 49 indexed citations
8.
Wang, Ruoyu, Jin Zhang, Wen‐Ming Cong, et al.. (2018). Impact of Preoperative Hepatitis B Virus Levels on Prognosis After Primary and Repeat Hepatectomies for Hepatocellular Carcinoma Patients—a Retrospective Study. Journal of Gastrointestinal Surgery. 22(5). 872–883. 6 indexed citations
9.
Yang, Yingyun, Ye Zhou, Jin Hou, et al.. (2017). Hepatic IFIT3 predicts interferon‐α therapeutic response in patients of hepatocellular carcinoma. Hepatology. 66(1). 152–166. 58 indexed citations
10.
Meara, Ellen, Jill R. Horwitz, Wilson M. Powell, et al.. (2016). State Legal Restrictions and Prescription-Opioid Use among Disabled Adults. New England Journal of Medicine. 375(1). 44–53. 200 indexed citations
11.
Zheng, Hao, Yuan Yang, Meng‐chao Wang, et al.. (2016). Low CDX1 expression predicts a poor prognosis for hepatocellular carcinoma patients after hepatectomy. Surgical Oncology. 25(3). 171–177. 11 indexed citations
12.
Roth, Gregory A., Jeanne E. Poole, Rebecca Zaha, et al.. (2016). Use of Guideline-Directed Medications for Heart Failure Before Cardioverter-Defibrillator Implantation. Journal of the American College of Cardiology. 67(9). 1062–1069. 50 indexed citations
13.
Yang, H. J., Yuan Yang, Lianghui Wang, et al.. (2016). A genetic variant of the NTCP gene is associated with HBV infection status in a Chinese population. BMC Cancer. 16(1). 211–211. 19 indexed citations
14.
Yan, Hongli, Yuan Yang, Ling Zhang, et al.. (2015). Characterization of the genotype and integration patterns of hepatitis B virus in early‐ and late‐onset hepatocellular carcinoma. Hepatology. 61(6). 1821–1831. 77 indexed citations
15.
Morden, Nancy E., Jeffrey C. Munson, Carrie H. Colla, et al.. (2014). Prescription Opioid Use Among Disabled Medicare Beneficiaries. Medical Care. 52(9). 852–859. 114 indexed citations
16.
Bekelis, Kimon, Elliott S. Fisher, Nicos Labropoulos, Weiping Zhou, & Jonathan Skinner. (2014). Variations in the Intensive Use of Head CT for Elderly Patients with Hemorrhagic Stroke. Radiology. 275(1). 188–195. 10 indexed citations
17.
Huang, Gang, Yuan Yang, Feng Shen, et al.. (2012). Early Viral Suppression Predicts Good Postoperative Survivals in Patients with Hepatocellular Carcinoma with a High Baseline HBV-DNA Load. Annals of Surgical Oncology. 20(5). 1482–1490. 32 indexed citations
18.
Huang, Gang, Eric C. H. Lai, Wan Yee Lau, et al.. (2012). Posthepatectomy HBV Reactivation in Hepatitis B–Related Hepatocellular Carcinoma Influences Postoperative Survival in Patients With Preoperative Low HBV-DNA Levels. Annals of Surgery. 257(3). 490–505. 97 indexed citations
19.
Li, Rui, Yin Yao Shugart, Weiping Zhou, et al.. (2008). Common genetic variations of the cytochrome P450 1A1 gene and risk of hepatocellular carcinoma in a Chinese population. European Journal of Cancer. 45(7). 1239–1247. 28 indexed citations
20.
Wu, Guicheng, Weiping Zhou, Shuhua Guo, et al.. (2003). The natural history of chronic hepatitis B: a retrospective study.. PubMed. 2(4). 566–70. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wallis Marsh Breakdown of academic impact, for papers by Allison J. Kwong Breakdown of academic impact, for papers by Hock Soo Ong Breakdown of academic impact, for papers by Jennifer A. Flemming Breakdown of academic impact, for papers by Chapy Venkatesan Breakdown of academic impact, for papers by Kwok-Hung Lai Breakdown of academic impact, for papers by James A. Knol Breakdown of academic impact, for papers by George Therapondos Breakdown of academic impact, for papers by Diamantis I. Tsilimigras Breakdown of academic impact, for papers by Cataldo Doria
Rankless by CCL
2026